GERN | Ticker Profile - Titan Protect

GERN

Geron Corporation

Healthcare · Biotechnology · NMS

$1.17

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$808M

Total market value of the company

Trailing P/E

N/A

Forward P/E

19.38

Based on estimated future earnings — lower means cheaper

Rev Growth

+30.9%

Year-over-year revenue change

Profit Margin

-34.3%

How much profit the company keeps from each dollar of revenue

ROE

-27.1%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$4.00

+242% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 5 analysts covering this stock

About Geron Corporation

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

https://www.geron.com

Country: United States Employees: 258 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

-0.414

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0985

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.492

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-38.8%

Historical annualised return based on price data

Max Drawdown

-79.0%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.68

Less volatile than the market — more defensive

52W High

$2.01

42% below the year high

52W Low

$1.04

12% above the year low

Avg Volume

17,403,950

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

10.9%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.11

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

53.28

Heavy leverage — higher financial risk if revenues decline

Current Ratio

6.78

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

4.85

Like current ratio but excludes inventory — stricter test

Gross Margin

61.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-0.5%

Profit from core operations before interest and tax

Free Cash Flow

$-92,136,624

Negative — the business is spending more than it generates

Revenue (TTM)

$196M

Total revenue over the last 12 months

Net Income

$-67,307,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$5.00

Target Median

$4.00

Target Low

$1.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go